At Venn Therapeutics, we are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of fibrosis and NASH.

  • VTX-001 is a monoclonal antibody that selectively targets integrin αvβ6/1 and has shown single-agent activity in multiple cancer models. VTX-001 safely blocks TGF-β1 and TGF-β3, completely avoiding blockage of TGF-β2; the blockage of TGF-β2 is associated with cardiac toxicity

  • VTX-001DX is a proprietary companion diagnostic that measures αvβ8 expression